Drug Trial Radar · NCT07489495
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
758
Planned (sponsor's estimate)
Start
Apr 9, 2026
Primary completion
Nov 27, 2030
Study completion Nov 27, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Exelixis
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone. The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
Conditions
- Carcinoma, Renal Cell
Interventions
BelzutifanDrug
Tablet for oral administration.
ZanzalintinibDrug
Tablet for oral administration.
PlaceboDrug
Zanzalintinib-matching placebo tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to approximately 30 months
- Overall Survival (OS)Time frame: Up to approximately 50 months
Locations
111 sites in 19 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center ( Site 0129)
Duarte, California · Recruiting
City of Hope Lennar Foundation Cancer Center ( Site 0142)
Irvine, California · Recruiting
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
Marietta, Georgia · Recruiting
University of Louisville, James Graham Brown Cancer Center ( Site 0133)
Louisville, Kentucky · Recruiting
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
Louisville, Kentucky · Recruiting
Beth Israel Deaconess Medical Center ( Site 0139)
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute ( Site 0135)
Boston, Massachusetts · Recruiting
The Cancer and Hematology Centers ( Site 0123)
Grand Rapids, Michigan · Recruiting
Washington University School of Medicine ( Site 0114)
St Louis, Missouri · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)
Hackensack, New Jersey · Recruiting
Atlantic Health System Morristown Medical Center ( Site 0109)
Morristown, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 0126)
New York, New York · Recruiting
The West Clinic, P.C. ( Site 0115)
Germantown, Tennessee · Recruiting
UT Southwestern Medical Center ( Site 0119)
Dallas, Texas · Recruiting
Instituto Alexander Fleming ( Site 0252)
CABA, Argentina · Recruiting
Centro Oncológico Riojano Integral ( Site 0256)
La Rioja, Argentina · Recruiting
COE (Centro Oncológico de Excelencia) ( Site 0259)
San Juan, Argentina · Recruiting
Centro Oncologico Korben ( Site 0254)
CABA, Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires ( Site 0253)
Ciudad de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
Río Cuarto, Córdoba Province, Argentina · Recruiting
Sanatorio Parque ( Site 0251)
Rosario, Santa Fe Province, Argentina · Recruiting
Instituto de Oncología de Rosario ( Site 0257)
Rosario, Santa Fe Province, Argentina · Recruiting
Macquarie University ( Site 2700)
Macquarie University, New South Wales, Australia · Suspended
Princess Alexandra Hospital ( Site 2703)
Woolloongabba, Queensland, Australia · Suspended
Peter MacCallum Cancer Centre ( Site 2702)
Melbourne, Victoria, Australia · Suspended
Fiona Stanley Hospital ( Site 2704)
Murdoch, Western Australia, Australia · Suspended
CEDOES ( Site 0303)
Vitória, Espírito Santo, Brazil · Recruiting
Instituto do Câncer e Transplante de Curitiba ( Site 0300)
Curitiba, Paraná, Brazil · Recruiting
Liga Norte Riograndense Contra o Câncer ( Site 0307)
Natal, Rio Grande do Norte, Brazil · Recruiting
Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
Ribeirão Preto, São Paulo, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
São José do Rio Preto, São Paulo, Brazil · Recruiting
The Ottawa Hospital Cancer Centre ( Site 0003)
Ottawa, Ontario, Canada · Recruiting
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
Québec, Quebec, Canada · Recruiting
IC La Serena Research ( Site 0405)
La Serena, Coquimbo Region, Chile · Recruiting
Clínica Puerto Montt ( Site 0404)
Port Montt, Los Lagos Region, Chile · Recruiting
Fundacion Arturo Lopez Perez ( Site 0401)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0400)
Santiago, Region M. de Santiago, Chile · Recruiting
ONCOCENTRO APYS ( Site 0403)
Viña del Mar, Valparaiso, Chile · Recruiting
Fakultni nemocnice Hradec Kralove ( Site 0902)
Hradec Králové, Czechia · Recruiting
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.